ID: 619
Titel: A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant treatments for early breast cancer.
Provsamlingsansvarig: Henrik Lindman
Start insamling: -
Slut insamling: -
Beskrivning: A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant treatments for early breast cancer.

PROVTYP;PROVGIVARE
Tumor tissue;26